Kazia Therapeutics KZIA
NASDAQ KZIA
$7.81 -0.26 (-3.22%)
At close: Oct 23, 2026 · 4:00 PM EDT

Kazia Therapeutics (KZIA) Cost of Revenue (2009)

Updated

Kazia Therapeutics' Cost of Revenue came in at $1.88 million for the year ended Jun 30, 2010.

Analysis

Kazia Therapeutics (KZIA) Cost of Revenue (2009) Analysis & Trends

  • Per Business Quant, earlier years put Cost of Revenue at $2 million in the year ended Dec 31, 2009.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 3.27 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 8.10 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 4.29 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 4.40 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 3.71 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 2.52 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 2.81 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn 1.58 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 4.09 Bn
10 Kazia Therapeutics 351,450.00 -52.02 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2009 871,000.00
API Access

Kazia Therapeutics Cost of Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=KZIA&period=max&api_key=YOUR_API_KEY